Core--Biologics Production

$126,184P01FY2008CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications & trials

Paper 37939122 Paper 34649272 Paper 33082277 Paper 32980545 Paper 32243637 Paper 31582553 Paper 31481510 Paper 30596402 Paper 30454872 Paper 30310789 Paper 30262560 Paper 28566329 Paper 28428282 Paper 28055107 Paper 27432875 Paper 27214069 Paper 27197068 Paper 26818003 Paper 26576864 Paper 26455717 Paper 26348890 Paper 26347113 Paper 26338894 Paper 26237500 Paper 26133724 Paper 26133610 Paper 26018193 Paper 25998714 Paper 25993198 Paper 25785845 Paper 25628467 Paper 25533035 Paper 25460570 Paper 25445025 Paper 25395425 Paper 25261237 Paper 25236531 Paper 25076159 Paper 24858425 Paper 24749780 Paper 24749757 Paper 24707941 Paper 24578502 Paper 24530971 Paper 23871782 Paper 23704203 Paper 23556108 Paper 23471305 Paper 23456518 Paper 23356514 Paper 23073268 Paper 22955187 Paper 22687452 Paper 22611160 Paper 22298418 Paper 22214546 Paper 21976541 Paper 21730271 Paper 21613259 Paper 21508413 Paper 21488858 Paper 20702781 Paper 20597486 Paper 20578815 Paper 20423225 Paper 20127945 Paper 20019612 Paper 19786617 Paper 19779884 Paper 19515724 Paper 19332764 Paper 19182204 Paper 19124831 Paper 19118002 Paper 18854559 Paper 18623377 Paper 18586921 Paper 18502830 Paper 18454687 Paper 18452065 Paper 18413376 Paper 18381107 Paper 18070719 Paper 17922043 Paper 17917964 Paper 17898567 Paper 17312330 Paper 17303693 Paper 16585217 Paper 16269863 Paper 16254140 Paper 15701869 Paper 15665621 Paper 14527031 Paper 13129395 Paper 12750161 Paper 12728403 Paper 11964278 Paper 11722986 Paper 11319588

Abstract

Core C is responsible for the production of clinical grade anti-CD45 BC8 antibody, anti-CD20 1F5(scFv)4-streptavidin fusion protein and anti CD45 BC8(scFv)4-streptavidin fusion proteins. These reagents will be produced, purified and validated in the Biologies Production Facility of the Fred Hutchinson Cancer Research Center. Antibodies and fusion proteins will be produced under current good manufacturing practice (cGMP) conditions and investigational new drug applications (INDs) will be filed with the Food and Drug Administration (FDA).

View original record on NIH RePORTER →